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Pirfenidone Inhibits Early Myointimal Proliferation but has No Effect on
Late Lesion Size in Rats
J. R. Waller∗, G. J. Murphy, G. R. Bicknell, R. Sandford, S. B. Margolin and M. L. Nicholson
Division of Transplant Surgery, University of Leicester
Aims: intimal hyperplasia is mediated by smooth muscle cell proliferation, migration and deposition of extracellular
matrix. The anti-fibrotic agent pirfenidone has been shown to inhibit pro-fibrotic growth factors in non-vascular
inflammatory models. This study investigated the effect of the novel anti-fibrotic agent pirfenidone on the development
of neointima.
Methods: male Sprague–Dawley rats received either standard diet or diet supplemented with pirfenidone (250, 500,
1000 mg/kg/day). Animals underwent left common carotid balloon angioplasty and were explanted at 4, 8, 14 and 28
days and analysed for intimal thickening, pro-fibrotic gene expression, extracellular matrix deposition and metalloproteinase
activity.
Results: neointimal thickness was significantly reduced in a dose-dependent manner at 14 days; pirfenidone 250 mg/kg
(p<0.005), pirfenidone 500 mg/kg (p<0.001), pirfenidone 1 g/kg (p<0.001). There were no significant differences in
intimal thickening at 28 days. Expression of MMP-2, MMP-9, TIMP-1, collagen III and TGF-beta were all significantly
inhibited at 14 days. Both collagen III expression and ECM deposition were reduced at 28 days (p<0.05 and <0.002
respectively).
Conclusion: pirfenidone reduces expression of MMPs governing smooth muscle cell proliferation and migration (MMP-
2 and 9), and genes favouring ECM accumulation (TIMP-1 and collagen III). This study shows that inhibition of MMP
activity is not sufficient to inhibit late lesion size.
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Introduction growth factor (PDGF),6,7 basic fibroblast growth factor
(bFGF)8,9 and transforming growth factor beta (TGF-
).10 These act as potent mitogens for medial VSMCs,Vascular smooth muscle cell (VSMCs) proliferation and
inducing a phenotypic ‘‘switch’’ from a quiescent con-migration along with the remodelling of extracellular
tractile state to a secretory proliferative form. Thismatrix proteins (ECM) result in a hyperplastic intimal
pivotal change is known as modulation.11,12 Mediallesion. These are pathophysiological responses to a
VSMC proliferation and migration through the internalvariety of stimuli including growth, hypertension and
elastic lamina requires the degradation of ECM andarterial injury. The formation of this ‘‘neointima’’ and
subsequently synthesis and deposition of new extra-subsequent lumenal narrowing are responsible for the
cellular proteins. Vascular smooth muscle cells arefailure of arterial reconstructive procedures in bypass
capable of producing metalloproteinases (MMPs) andsurgery,1 restenosis following transluminal an-
serine proteases as well as ECM. MMPs are a familygioplasty2 and arterial vasculopathy in transplanted
of Zn2+-dependent proteases that differ widely in sub-grafts.3 Importantly, intimal hyperplasia predisposes to
strate specificity and are not only capable of degradingsuperimposed atherosclerotic changes, plaque rupture
matrix, but can also activate other metalloproteinases.13and vessel occlusion.4,5
Secretion of metalloproteinases, principally MMP-2Following mechanical or immune-mediated arterial
and 9 facilitate the migration of VSMCs across theinjury macrophages, platelets and VSMCs release a
internal elastic laminae, whilst TIMPs inhibit this pro-myriad growth factors including platelet-derived
cess.14 Conversely, extracellular matrix deposition is
characterised by a relative increase in protease in-
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bypass graft survival or prevent restenosis following Sirius red staining
balloon angioplasty.
To date, no pharmacological agents have proved Carotid arteries were formalin fixed, embedded in
epoxy resin and cut into 4 m sections. The resin waseffective in the clinical setting. Pirfenidone (5-methyl-
1-phenyl-2-(1H)-pyridone) is a novel anti-fibrotic and removed in xylene for 10 min and dehydrated in serial
washes of 100% alcohol for 2 min performed twice,anti-proliferative agent which has been shown to in-
hibit smooth muscle cell proliferation and deposition 95%, 80% and 60% alcohol for 2 min. Sections were
run under cold running water for 10 min and finallyof ECM proteins in animal models of fibrosis.16–18 In
the present study, we administered pirfenidone to rinsed briefly with distilled water. Staining was per-
formed overnight for 12 h in picro–sirius red F3BAassess its effect on the development of the neointima.
(0.1% Sirius red F3BA in saturated aqueous picric
acid). Rapid dehydration was repeated with an initial
wash of 0.01 M HCl for 2 min, and serial washes of
70% alcohol for 45 s followed by 80%, 95% and 100%
Material and Methods for 2 min. Slides were cleared with 2 washes of xylene
for 2 min, excess xylene removed and slides mounted
Arterial injury model with Xam organic mountant. Ten random windows of
intima were analysed and the value of extracellular
Four-month-old male Sprague–Dawley rats (weighing matrix was determined from the mean of these
350–400 g) were obtained from Harland (Cambridge, windows.
U.K.). Rats were anaesthetised with halothane and
were cared for in accordance with Animals (Scientific
Procedures) Act 1986. The left common carotid artery Molecular analysis
was denuded of endothelium with a saline-filled 2F
balloon embolectomy catheter (Baxter Healthcare The methods used to quantify levels of mRNA ex-
pression using reverse transcriptase–polymerase chainCorp) as described previously.19 In brief, the catheter
was introduced through the left external carotid artery reaction (RT–PCR) have been described previously.20
In brief, vessels were cut into 10 m sections andinto the common carotid. Denudation was performed
by inflating the catheter to a pressure of 2 atmospheres ground under liquid nitrogen in a mortar and pestle.
Messenger RNA was extracted using oligo-dT-linkedand passing it in a twisting manner from the arch of
the aorta to the carotid bifurcation. This procedure Dynabeads (Dynal, Bromborough, U.K.). Competitive
reverse transcriptase–polymerase chain reaction (RT–was repeated twice more before the catheter was re-
moved and the external carotid ligated. PCR) was performed as described previously. Genes
chosen for quantification in this study included matrixThe rats were anaesthetised at 4, 8, 14 and 28 days
post balloon injury and the left common carotid artery metralloproteinases (MMPs)-2 and 9, tissue inhibitor
of metalloproteinases (TIMP-1), matrix protein col-flushed with phosphate-buffered saline. The middle
third of each vessel was used for histomorphometry lagen III and transforming growth factor- (TGF-).
All probes and primers were designed from sequencesand the outer thirds snap frozen in liquid nitrogen
and stored at −70 °C for molecular studies. available on the EMBL database using the program
GCG prime (Genetics Computer Group, Madison, Wis-
consin, U.S.A.) and synthesised by Life Technologies
(Paisley, U.K.) or Genosys Biotechnologies Europe
(Pampisford, U.K.). Quantification of RT–PCR prod-
Morphology ucts was performed using an enzyme-linked im-
munosorbent assay. Differences in tissue cellularity
Vessels for histological study were not pressure per- were corrected for by expressing values of com-
fused but fixed with 2.5% gluteraldehyde in 0.1 M plementary DNA product as a ratio to that of con-
phosphate buffer (pH 7.4). After 16 h further fixation, stitutively expressed housekeeping gene, -actin.
the vessels were embedded in epoxy resin and cut
into 2 m transverse sections. Intimal and medial areas
were assessed using light microscope assisted com- Gelatin zymography
puter planimetry. Intimal and medial areas were de-
fined by internal and external elastic laminae Metalloproteinases were extracted from frozen tissue
as described previously.21 Briefly, frozen tissue wasrespectively.
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thawed over ice, weighed, chopped into 1 mm2 pieces
and homogenised in buffer (urea 2 mM, Tris-HCl
50 mM pH 7.6, NaCl 137 mM, EDTA 1 g/l, Brij-35 1/
ml/l and PMSF 0.1 mM – all Sigma, Poole, (U.K.). The
homegenate was then centrifuged at 12 000 g for 1 h
at 4 °C and the resulting supernatants dialysed
(12–14 000 kDa) against a dialysing buffer (Tris 25 mM
pH 8.5, CaCl2 10 mM, 0.1% Brij-35, 0.1 mM PMSF) for
18 h att 4 °C. The protein concentration of each sample
was standardised as described previously.22 Equivalent
protein loads (15 g) were resolved by a non-reducing
electrophoresis through a 10% SDS-polyacrylamide
gel impregnated with 1 mg/ml gelatin. The human
fibrosarcoma cell line, HT-1080, was loaded onto each
gel as a positive control. SDS was removed from the
gels by incubation in 2.5% Triton X-100 (3×15 min)
and the gels immersed for 16 h in incubation buffer
(50 mM Tris-HCl, 10 mM CaCl and 0.05% Brij-35,
pH 7.4) at 37 °C. Gels were fixed and stained in 0.1%
Coumassie brilliant blue in 50% methanol/20% acetic Fig. 1. Bar graph showing dose-dependent inhibition of intima
media ratios by pirfenidone at 14 days. Bars represent means andacid/30% double-distilled water for 2 h. Proteinases
error bars 95% confidence intervals of means. Each dose representswere visualised as clear bands of lysis against a dark 6 rats at 14 days. Chi square=17.3; df=3; p<0.001.
background of intact substrate. The relative density
of each lytic band was determined from negative showed 10% weight loss over this period compared
photographic images of gels with a Pharmacia LKB to controls and thus pirfenidone was administered at
Imagemaster scanning densitometer (Pharmacia LKB, a dose of 500 mg/kg/day throughout the remainder
St. Albans, Herts, U.K.) and expressed as a product of of the study.
the optical density and area of the band. This method ‘‘Uninjured’’ rat arteries do not contain smooth
provides a semi-quantitative analysis of metallo- muscle cells in the intima.23 However, smooth muscle
proteinase activity. cells appeared in the intima of untreated rats 4 days
post arterial injury, median intima medial ratio 0.08
(range 0.04–0.14) (Fig. 2A). Smooth muscle migration
was completely inhibited by continuous daily oral
Statistical analysis administration of pirfenidone at 500 mg/kg/day
(p<0.002) (Fig. 2). Intimal thickening was reduced in
Intima medial ratios, collagen staining and RT–PCR pirfenidone treated rats at day 8, intima medial ratio
data are presented as median±range from 6 animals 0.38 (range 0.11–0.61) compared with controls, intima
per group. Differences between control and treatment medial ratio 0.54 (range 0.26–0.93), p<0.01 (Figures 2C
groups were calculated using non-parametric analysis and D respectively). A significant reduction in intimal
(Mann–Whitney U-test). The relative density of sub- thickening was also observed at 14 days, intima medial
strate gel lysis was quantified from 3 carotids in each ratio 0.49 (range 0.12–0.85) versus untreated rats, in-
treatment group and run on the same gel. Differences tima medial ratio 1.54 (range 1.02–2.04) p<0.001 (Fig-
were again expressed using non-parametric analysis. ures 2E and F respectively). However, no significant
Differences were considered significant at Ζ0.05. differences in intimal thickening were observed at 28
days (Figures 2G, H and Figure 3). Pirfenidone had
no significant effect on medial area compared with
controls at any time point (data not shown).
Results
Stereological analysis
Effect of pirfenidone on -actin mRNA expression
Pirfenidone inhibited intimal thickening at 14 days in
a dose-dependent manner (p<0.001) (Fig. 1). Animals RT–PCR was performed on carotid arteries from both
control and treated animals to assess whether -actintreated with pirfenidone at a dose of 1 g/kg/day
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Fig. 2. Representative transverse cross-sections demonstrating the
effect of pirfenidone (500 mg/kg) on the development of noeintimal
formation at 4 days (Control – A, Pirfenidone – B) 8 days (Control
– C, Pirfenidone – D), 14 days (Control – E, Pirfenidone – F) and
Fig. 4. Molecular data at 14 days: Values are expressed as medians28 days (Control – G, Pirfenidone – H). The arrow represents the
with standard error of means shown. The value of messengerinternal elastic lamina (IEL).
(mRNA) expression is stated in arbitary units and expressed as a
ratio to that of housekeeping gene -actin.
mRNA expression was affected by the administration
of pirfenidone. No differences were found between
control and treated animals at any time point assessed,
confirming that expression of the house-keeping gene
-actin was not affected by either balloon injury or
treatment with pirfenidone (data not shown).
Effect of pirfenidone on pro-fibrotic gene expression
The results at 14 days are shown in Figure 4 and
expressed as mean values (±SEM). Gene data pre-
sented is standardised relative to the house-keeping
Fig. 3. Bar graph showing intima medial ratios 4, 8, 14 and 28 days gene -actin. Pirfenidone significantly inhibited MMP-
post arterial balloon injury. Intima media ratios significantly reduced 2, MMP-9, TIMP-1, TGF- and collagen III expression
in pirfenidone treated rats (500 mg/kg/day) at 14 days: p<0.001.
at 14 days (p<0.001). These observations were not seen
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however at 28 days, when only collagen III mRNA
was reduced in the Pirfenidone treated group, median
value 0.87 (range 0.84–0.91) compared with controls,
1.12 (0.85–1.67) p<0.05.
Metalloproteinase activity
A representative gelatin zymogram is shown in Figure
6. Control samples demonstrated lytic bands at 92 kDa,
82 kDa and 72 kDa consistent with MMP-9, pro and
active forms of MMP-2 respectively. Pirfenidone-
treated samples also demonstrated clear lytic bands
corresponding to pro and active MMP-2. However,
densitometric analysis showed a significant reduction
in MMP-9 activity in pirfenidone-treated carotids at
day 4, median value 0.1 (range 0.02–0.2) compared
with controls, 0.39 (0.27–0.63) p<0.002. Pro and active
MMP-2 were reduced in pirfenidone-treated carotids
at day 4 although this failed to reach statistical sig-
nificance (p<0.1). MMP-9 activity was not detected at
any other time point, consistent with previous find-
ings.24 There were no significant differences in pro and
active MMP-2 activity at any other time point.
Extracellular matrix deposition
Pirfenidone attenuated neointimal extracellular matrix
deposition at 28 days; median value 15 (range 12–19)
compared with controls, 9 (range 7–12) (p<0.002). Fig. 5. Molecular data at 28 days: Values are expressed as medians
with standard errors of means shown. The value of messenger
(mRNA) expression is stated in arbitary units and expressed as a
ratio to that of housekeeping gene -actin.
Discussion
This study shows pirfenidone to inhibit early vascular
smooth muscle proliferation and migration following no effect on metalloproteinase expression at this later
time point (Fig. 5).arterial injury but fails to inhibit late intimal pro-
liferation at 28 days. Furthermore, the gene data pre- Vascular smooth muscle cells constitutively express
MMP-2 under basal conditions whilst MMP-9 ex-sented suggests that its mechanism of action is due
to inhibition of MMP 2 and 9 transcription. Gelatin pression is induced by arterial injury.25 It is therefore
likely that the observed reduction in early intimalzymography showed pirfenidone to significantly in-
hibit MMP-9 activity. Whilst the reduction in pro thickening is attributable to inhibition of MMP-2 and
9 in rats treated with pirfenidone. Previous studiesand active MMP-2 activity failed to reach statistical
significance (p<0.065 and p<0.093 respectively), it is using metalloproteinase inhibitors support this hypo-
thesis: Southgate et al. showed synthetic MMP in-likely that pirfenidone also has an inhibitory effect on
MMP-2 activation. Despite significant differences in hibitors significantly inhibited smooth muscle cell
proliferation and migration from rabbit aortic explantsintimal lesion size at day 14, continued administration
of pirfenidone failed to confer this reduction in intimal in vivo26 and Bendeck et al. showed a significant re-
duction in intimal hyperplasia up to 10 days post ratthickening to 28 days. Additionally, pirfenidone had
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deposition has been previously observed in a bleo-
mycin hamster model of fibrosis and this also occurred
at a transcriptional level.38
In conclusion, we have shown pirfenidone to at-
tenuate early intimal thickening and significantly inhibit
metalloproteinase gene expression governing medial
smooth muscle cell proliferation and migration, and
collagen deposition. The findings of this study support
the hypothesis that metalloproteinases are pivotal me-
diators in vascular smooth muscle cell proliferation and
migration. However we have shown that inhibition of
Fig. 6. Representative zymogram of homegenates for paired samples metalloproteinases alone is not sufficient to inhibit late
for control and Pirfenidone treated rats (n=3) at 4, 8, 14 and 28 lesion formation and other pathways must be inhibited
days post arterial injury. Human fibrosarcoma line HT1080 serves
to address delayed migration and intimal proliferation.as positive control for matrix metalloproteinases 2 and 9.
carotid ballon injury using the non-selective MMP-
Acknowledgementsinhibitor GM-6001.27 Proliferation studies dem-
onstrated a prolonged period of intimal vascular
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Fellowship.accelerated increase in late lesion size. The reduction
of TIMP-1 expression is more difficult to interpret
since the role of TIMP-1 in the development of intimal
lesions is complex. TIMP-1 is the major endogenous
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